CA2686396A1 - Controlled release oral formulations of ion channel modulating compounds and related methods for preventing arrhythmia - Google Patents

Controlled release oral formulations of ion channel modulating compounds and related methods for preventing arrhythmia Download PDF

Info

Publication number
CA2686396A1
CA2686396A1 CA002686396A CA2686396A CA2686396A1 CA 2686396 A1 CA2686396 A1 CA 2686396A1 CA 002686396 A CA002686396 A CA 002686396A CA 2686396 A CA2686396 A CA 2686396A CA 2686396 A1 CA2686396 A1 CA 2686396A1
Authority
CA
Canada
Prior art keywords
mammal
arrhythmia
vernakalant hydrochloride
ion channel
channel modulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002686396A
Other languages
English (en)
French (fr)
Inventor
Jeffery Jerome Wheeler
Gregory N. Beatch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cardiome Pharma Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2686396A1 publication Critical patent/CA2686396A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
CA002686396A 2007-05-04 2008-05-02 Controlled release oral formulations of ion channel modulating compounds and related methods for preventing arrhythmia Abandoned CA2686396A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US91612907P 2007-05-04 2007-05-04
US60/916,129 2007-05-04
US6615607P 2007-08-01 2007-08-01
US61/066,156 2007-08-01
US3411908P 2008-03-05 2008-03-05
US61/034,119 2008-03-05
US3719808P 2008-03-17 2008-03-17
US61/037,198 2008-03-17
PCT/US2008/062551 WO2008137778A2 (en) 2007-05-04 2008-05-02 Controlled release oral formulations of ion channel modulating compounds and related methods for preventing arrhythmia

Publications (1)

Publication Number Publication Date
CA2686396A1 true CA2686396A1 (en) 2008-11-13

Family

ID=39691347

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002686396A Abandoned CA2686396A1 (en) 2007-05-04 2008-05-02 Controlled release oral formulations of ion channel modulating compounds and related methods for preventing arrhythmia

Country Status (19)

Country Link
US (3) US20080312309A1 (enExample)
EP (3) EP2155334A2 (enExample)
JP (1) JP2010526102A (enExample)
KR (1) KR20100017648A (enExample)
CN (1) CN101711174A (enExample)
AU (1) AU2008247508B2 (enExample)
BR (1) BRPI0810697A2 (enExample)
CA (1) CA2686396A1 (enExample)
CO (1) CO6241136A2 (enExample)
CR (1) CR11117A (enExample)
EA (1) EA200971025A1 (enExample)
EC (1) ECSP099777A (enExample)
IL (1) IL201934A0 (enExample)
MA (1) MA31664B1 (enExample)
MX (1) MX2009011929A (enExample)
NI (1) NI200900196A (enExample)
NZ (1) NZ581351A (enExample)
TN (1) TN2009000461A1 (enExample)
WO (1) WO2008137778A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7345086B2 (en) * 2003-05-02 2008-03-18 Cardiome Pharma Corp. Uses of ion channel modulating compounds
US20090041841A1 (en) * 2003-05-02 2009-02-12 Cardiome Pharma Corp. Controlled release tablet formulations for the prevention of arrhythmias
US20110198492A1 (en) * 2010-02-18 2011-08-18 Black David L Detection and Quantitation of Pain Medications in Oral Fluid Specimens

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69126064T2 (de) * 1990-06-22 1997-08-28 Hoffmann La Roche Nachweis von schwachen Metabolisierungsreagentien von Drogen
US5891696A (en) 1996-08-02 1999-04-06 Panvera Corporation Compositions for cytochrome P450 biotransformation reactions
JP3176342B2 (ja) 1997-08-13 2001-06-18 ファイザー製薬株式会社 薬剤代謝の評価方法及び前記方法用の試薬組成物
CN1217918C (zh) * 1998-04-01 2005-09-07 卡迪欧梅制药公司 氨基环己基醚化合物和其用途
US7507545B2 (en) * 1999-03-31 2009-03-24 Cardiome Pharma Corp. Ion channel modulating activity method
US7524879B2 (en) * 2000-10-06 2009-04-28 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
US7057053B2 (en) * 2000-10-06 2006-06-06 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
EP1281755A3 (en) * 2001-07-31 2003-06-18 Pfizer Products Inc. Variants of the human cyp2d6 gene
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
US7345086B2 (en) * 2003-05-02 2008-03-18 Cardiome Pharma Corp. Uses of ion channel modulating compounds
US20080063707A1 (en) * 2003-05-02 2008-03-13 Cardiome Pharma Corp. Controlled release tablet formulations for the prevention of arrhythmias
CA2524034A1 (en) * 2003-05-02 2004-11-18 Cardiome Pharma Corp. Uses of ion channel modulating compounds
US20090041841A1 (en) * 2003-05-02 2009-02-12 Cardiome Pharma Corp. Controlled release tablet formulations for the prevention of arrhythmias
DE60305200T2 (de) * 2003-05-02 2007-05-10 Cardiome Pharma Corp. Aminocyclohexylether-verbindungen und deren verwendung
WO2005018635A2 (en) * 2003-08-07 2005-03-03 Cardiome Pharma Corp. Ion channel modulating activity i
US7345087B2 (en) 2003-10-31 2008-03-18 Cardiome Pharma Corp. Aminocyclohexyl ether compounds and uses thereof
US7705036B2 (en) * 2004-04-01 2010-04-27 Cardiome Pharma Corp. Deuterated aminocyclohexyl ether compounds and processes for preparing same
JP5583325B2 (ja) * 2004-11-08 2014-09-03 カーディオム ファーマ コーポレイション イオンチャネル調節化合物の投与レジメ
JP5159616B2 (ja) * 2005-06-15 2013-03-06 カーディオム ファーマ コーポレイション アミノシクロヘキシルエーテル化合物の調製のための合成プロセス
WO2009018547A1 (en) * 2007-08-01 2009-02-05 Cardiome Pharma Corp. Extended release formulations containing an ion-channel-modulating compound for the prevention of arrhythmias

Also Published As

Publication number Publication date
NI200900196A (es) 2010-03-11
WO2008137778A2 (en) 2008-11-13
CR11117A (es) 2010-02-19
EP2462933A1 (en) 2012-06-13
EA200971025A1 (ru) 2010-04-30
IL201934A0 (en) 2010-06-16
TN2009000461A1 (en) 2011-03-31
ECSP099777A (es) 2010-02-26
WO2008137778A3 (en) 2009-03-12
MA31664B1 (fr) 2010-09-01
US20160089361A1 (en) 2016-03-31
US20080312309A1 (en) 2008-12-18
JP2010526102A (ja) 2010-07-29
EP2155334A2 (en) 2010-02-24
NZ581351A (en) 2012-07-27
US20150099788A1 (en) 2015-04-09
AU2008247508A1 (en) 2008-11-13
AU2008247508B2 (en) 2014-07-10
CN101711174A (zh) 2010-05-19
EP2468278A1 (en) 2012-06-27
MX2009011929A (es) 2010-03-08
CO6241136A2 (es) 2011-01-20
BRPI0810697A2 (pt) 2019-08-27
KR20100017648A (ko) 2010-02-16

Similar Documents

Publication Publication Date Title
EP2974720B1 (en) Mosapride sustained-release preparation for providing pharmacological clinical effects with once-a-day administration
EP1441713B2 (en) Modified release tamsulosin tablets
US20140242159A1 (en) Method for Preparing a Granulate Formulation of Pirfenidone and Pharmaceutically Acceptable Excipients
US10188637B2 (en) Granulate formulation of 5-methyl-1-phenyl-2-(1H)-pyridone and method of making the same
JP2009500317A (ja) 放出特性改良医薬組成物およびその製造方法
KR20150028367A (ko) 히드로모르폰 및 날록손을 포함하는 제약 조성물
KR20090016611A (ko) 메만틴의 약학 조성물
CA3091259A1 (en) Sustained release formulations of bempedoic acid
US20160089361A1 (en) Controlled release oral formulations of ion channel modulating compounds and related methods for preventing arrhythmia
US20230301941A1 (en) Abuse-deterrent dosage forms containing esketamine
ES2704979T3 (es) Formulaciones galénicas de aliskiren e hidroclorotiazida
US8883207B2 (en) Controlled release carvedilol formulation
KR102545579B1 (ko) iLet (innovation low excipient tablet) 기술을 이용한 정제사이즈 축소를 통해 복용편의성이 증가된 카르베딜롤 서방성 정제
EP3697392A1 (en) Tablets comprising tamsulosin and solifenacin
WO2023247435A1 (en) Bilayer tablets of valsartan and indapamide
EP2663283B1 (en) High drug load tablet formulation of brivanib alaninate
US20080063707A1 (en) Controlled release tablet formulations for the prevention of arrhythmias
CN106955273B (zh) 一种含有钠-葡萄糖协同转运蛋白2抑制剂的药物组合物
WO2009018547A1 (en) Extended release formulations containing an ion-channel-modulating compound for the prevention of arrhythmias
EP1889629B1 (en) Stable formulation comprising a combination of a moisture sensitive drug and a second drug and manufacturing procedure thereof
JP2009538905A (ja) 感湿性薬物を含んで成る安定性製剤及びその製造方法
JP2009542806A (ja) 感湿性薬物及び第２薬物の組合せを含んで成る安定製剤及びその製造方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130425

FZDE Discontinued

Effective date: 20170502